NZ731834A - Compositions for use in treating heavy menstrual bleeding and uterine fibroids - Google Patents
Compositions for use in treating heavy menstrual bleeding and uterine fibroidsInfo
- Publication number
- NZ731834A NZ731834A NZ731834A NZ73183414A NZ731834A NZ 731834 A NZ731834 A NZ 731834A NZ 731834 A NZ731834 A NZ 731834A NZ 73183414 A NZ73183414 A NZ 73183414A NZ 731834 A NZ731834 A NZ 731834A
- Authority
- NZ
- New Zealand
- Prior art keywords
- uterine fibroids
- menstrual bleeding
- treating heavy
- compositions
- heavy menstrual
- Prior art date
Links
- 206010046798 Uterine leiomyoma Diseases 0.000 title abstract 2
- 201000010260 leiomyoma Diseases 0.000 title abstract 2
- 208000007106 menorrhagia Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
- 229950004823 elagolix Drugs 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 229960001652 norethindrone acetate Drugs 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are methods of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4- methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl]-l-phenyl-ethylamino)-butyric acid (Elagolix) or a pharmaceutically acceptable salt thereof, in combination with estrogens (e.g., estradiol) and progestogens (e.g., norethindrone acetate).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788821P | 2013-03-15 | 2013-03-15 | |
| NZ63172414 | 2014-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ731834A true NZ731834A (en) | 2018-08-31 |
Family
ID=66476968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ731834A NZ731834A (en) | 2013-03-15 | 2014-03-14 | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ731834A (en) |
-
2014
- 2014-03-14 NZ NZ731834A patent/NZ731834A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4223298A3 (en) | Compositions for use in treating heavy menstrual bleeding | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| NZ732154A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MX2020010412A (en) | Inhibitors of bruton's tyrosine kinase. | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| MX2021007268A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof. | |
| MX2015012005A (en) | Bromodomain inhibitors. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| UA116824C2 (en) | Oral formulations of pyrrolidine derivatives | |
| TR201911232T4 (en) | Topical compositions containing the extract of coriolus versicolor for the development of autoimmunity. | |
| MX2016002580A (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases. | |
| BR112015030387A2 (en) | pyrazole compounds as fshr modulators and uses thereof | |
| EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| MX2015017879A (en) | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase. | |
| NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor | |
| MX2016005092A (en) | Vaginal inserted estradiol pharmaceutical compositons and methods. | |
| MY172530A (en) | Method for treating gynecological diseases | |
| WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment | |
| MX2015012153A (en) | Pyrrolopyrimindine cdk9 kinase inhibitors. | |
| CL2015003014A1 (en) | Pharmaceutical composition comprising 0.5-5 mg of (11?, 17?) - 17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one ; oral dosage form; use to treat and / or prevent a gynecological disease, such as fibroids in the uterus, endometriosis or excessive menstrual hemorrhages. | |
| WO2016164460A3 (en) | Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject | |
| NZ731834A (en) | Compositions for use in treating heavy menstrual bleeding and uterine fibroids | |
| MX2016010482A (en) | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 MAR 2021 BY SPRUSON + FERGUSON Effective date: 20190131 |
|
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY THOMSON REUTERS Effective date: 20210206 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY THOMSON REUTERS Effective date: 20220302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2024 BY THOMSON REUTERS Effective date: 20230201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2025 BY THOMSON REUTERS Effective date: 20240201 |